Medicines

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Japan's Mitsui & Co said on Thursday it had teamed up with Rohto Pharmaceutical Co to buy Eu Yan Sang International in a deal valuing the Singapore-based traditional Chinese medicines firm at S$800 million ($594 million).

Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang

Genetic medicines company Passage Bio PASG, +0.00% set the terms for its planned initial public offering on Tuesday, with plans to offer 7.4 million shares priced at $16 to $18 each.

Genetic medicines company Passage Bio to offer 7.4 million shares in IPO priced at $16 to $18 each

Agile Therapeutics

Agile Could Reach $10/Share After Twirla Approval

AbbVie

Allergan

Bristol-Myers

Celgene

Eli Lilly

Merck

Novartis

Pfizer

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Canopy Growth

Esperion Therapeutics

OrganiGram Holdings Inc.

Regeneron Pharmaceuticals

Marijuana beverages, edibles, and vapes are finally available in Canada, but marijuana stocks still have big obstacles to overcome.

Can Cannabis 2.0 Kickstart Marijuana Stocks?

Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.

Here's Why The Medicines Company Jumped 60% in November

Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market

One drug is at the center of the deal: inclisiran. Here is what it does and what RNA interference is.

Why Novartis Is Buying The Medicines Company For $9.7 Billion

Arrowhead Pharmaceuticals

Clovis Oncology

Dicerna Pharmaceuticals

Sorrento Therapeutics Inc

A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?

The Return of M&A Activity Is Lifting These Biotech Stocks Today

Biotechnology ETFs led the charge on Monday after Novartis AG (NYSE: NVG) agreed to buy Medicine Co. (NasdaqGS: MDCO) as the Swiss multinational pharmaceutical company moves to expand its treatment for complex conditions.

Biotech ETFs Pop After Novartis Acquires Medicines Co.

Novartis added another key piece to the puzzle over the weekend.

Why The Medicines Company Stock Is Soaring Today

AMTD International Inc

LVMH Moet Hennessy Louis Vuitton

Charles Schwab

Tiffany & Co.

While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.

Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G.

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Happy Monday. A version of this story first appeared in CNN Business' Before the Bell newsletter. Not a subscriber? You can sign up right here.

Merger Monday: Three major deals and one that could turn hostile

Novartis AG agreed to buy Medicines Co. for about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of recent acquisitions for Chief Executive Officer Vas.

Novartis To Buy Medicines Co. In $6.8 Billion Deal For Key Drug

Amgen

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Novartis will buy The Medicines Company for $9.7 billion, adding a promising cholesterol treatment to its wheelhouse, the Swiss pharma giant announced Sunday.
The post Novartis Announces $9.7 Billion Takeover Of The Medicines Company appeared first on Investor's Business Daily.

Novartis Announces $9.7 Billion Takeover Of The Medicines Company

Novartis has agreed to pay $85 a share for Medicines Company in a deal that could be reached this weekend, according to The Wall Street Journal.

Novartis reportedly nears deal to buy cholesterol drugmaker Medicines Company for $7 billion

Swiss drugmaker Novartis AG  is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co  for about $7 billion, the Wall Street Journal reported on Saturday.

Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ

The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.

The Medicines Company Soars Amid Acquisition Whispers

Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

Implied Volatility Surging for Medicines Company (MDCO) Stock Options

The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.

Medicines Company Up on Rumors of Potential Buyout by Novartis

Here’s Why The Medicines Company Jumped Higher Again Today

Medicines Co. (NASDAQ: MDCO) shares shot up on Tuesday after it was reported that Novartis A.G.

Will Medicines Co Be the Next Target of Novartis?

Shares of The Medicines Company (NASDAQ: MDCO), which have climbed over 200% in the year-to-date period, are seeing further momentum Tuesday following a Bloomberg report of takeover interest.

News for Medicines Stock (MDCO)